A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma

British Journal of Haematology

Volumn 94, Issue 4, 1996, Pages 659-664

  Abrahamson, G M ^a   Bird, J M ^a   Newland, A C ^b   Gaminara, E ^a   Giles, Chrissie ^a   Joyner, M ^a   Kelsey, S M ^b   Lewis, D ^a   Mccarthy, D M ^a   Roques, A W ^a   Tew, C J ^a   Treacy, M ^a   Van De Pette, J ^a   Samson, Diana ^a,c  

^a Riverside Haematology Group   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alpha interferon; Induction therapy; Maintenance therapy; Multiple myeloma; VAD chemotherapy

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9544257388     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1852.x     Document Type: Article

References (18)

1. Alexanian, R., Barlogie, B. & Gutterman, J. (1991) Alpha-interferon combination therapy of resistant myeloma. American Journal of Clinical Oncology, 14, 188-192.
2. Belch, A., Shelley, W. & Bergsagel, D. (1988) A randomised trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. British Journal of Cancer, 57, 94-98.
3. Cooper, M.R., Dear, K., McIntyre, O.R., Ozer, H., Ellerton, J., Canellos, G., Bernhardt, B., Duggan, D., Faragher, D. & Schiffer, C. (1993) A randomised clinical trial comparing melphalan prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 11, 155-160.
4. Corrado, C., Pavlosky, J., Saslasky, J., Lein, J., Palau, V. & Santarelli, M.T. (1989) Randomised trial comparing melphalan prednisolone with or without recombinant α2-interferon in multiple myeloma. Proceedings of the American Society for Clinical Oncology, 2, 258.
5. Durie, B. & Salmon, S. (1975) A clinical staging system for multiple myeloma. Cancer, 36, 842-854.
6. Durie, B.G.M., Dixon, D.O., Carter, S., Stephens, R., Rivkin, S., Bonnet, J., Salson, S.E., Dabich, L., Files, J.C. & Costanzi, J.J. (1986) Improved survival with combination chemotherapy induction for multiple myeloma: a Southwestern Oncology Group study. Journal of Clinical Oncology, 4, 1227-1237.
7. Ludwig, H., Cohen, A.M., Huber, H., Nachbaur, D., Jungi, W.F., Senn, H., Gunczler, P., Schuller, J., Eckhardt, S., Seewann, H.L., Cavalli, F., Fritz, E. & Micksche, M. (1991) Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. European Journal of Cancer, 27, (Suppl. 4), S40-S45.
8. MacLennan, I.C.M., Chapman, C., Dunn, J. & Kelly, K. (1992) Combination chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet, 339, 200-205.
9. Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauto, V.M., Marmont, F., Petrucci, M.T., Tribalto, M., Vegna, M.L., Damacco, F. & Pileri, A. (1990) Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine, 322, 1430-1434.
10. Montuoro, A., de Rosa, L., de Blasio, A., Pacilli, L., Petti, N. & de Laurenzi, A. (1990) Alpha-2-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. British Journal of Haematology, 76, 365-368.
11. Osterborg, A., Bjorkman, M., Bjoremann, M., Brenning, G., Carlson, K., Celsing, F., Gahrton, G., Grimfors, G., Gyllenhammer, H., Hast, R., Johansson, B., Juliusson, G., Jarnmark, M., Kimby, E., Lerner, R., Linder, O., Merk, K., Nilsson, B., Ohrling, M., Paul, C., Simonsson, B., Smedbyr, B., Svedmyr, E., Stafelt, A.-M., Strander, H., Uden, A.-M., Osby, E. & Mellstedt, H. (1993) Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages, II and III: a randomised study from the Myeloma Group of Central Sweden. Blood, 81, 1428-1434.
12. Peest, D., Deicher, D., Coldewey, R., Leo, R., Bartl, R., Bartels, H., Braun, H.J., von Broen, I.M., Fischer, J.T., Gramatzki, M., Hein, R., Henke, R., Hoffman, L., Kreuser, E.D., Maier, W.D., Meier, C.R., Oertel, J., Planker, M., Reinhold, H.M., Schafer, E., Schumacher, E., Selbach, J., Stennes, M., Stenzinger, W., Tirier, C., Wagner, H., Weh, H.J. & Wysk, J. (1990) Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) induction chemotherapy and interferon maintenance treatment in multiple myeloma: current results of a multicentre trial. Onkologie, 13, 458-460.
13. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. British Journal of Cancer, 31, 1-39.
14. Quesada, J.R., Alexanian, R., Hawkins, M., Barlogie, B., Borden, E., Itri, L. & Gutterman, J.U. (1986) Treatment of multiple myeloma with recombinant alpha-interferon. Blood, 67, 257-278.
15. Salmon, S.E. & Crowley, J. (1993) Evaluation of interferon (IFN) in maintenance therapy for myeloma. Abstracts of IVth International Workshop on Multiple Myeloma. Rochester, 91.
16. Samson, D. (1994) The role of interferon in the management of multiple myeloma. Leukaemia and Lymphoma, 2, 67-74.
17. Samson, D., Gaminara, E., Newland, A., van de Pette, J., Kearney, J., McCarthy, D., Joyner, M., Aston, L., Mitchell, T., Hamon, M., Barrett, A.J. & Evans, M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, ii, 882-885.
18. Westin, J., Rodjer, S., Turesson, I., Cortelezzi, A., Hjorth, M. & Zador, G. (1995) Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. British Journal of Haematology, 89, 561-568.